7 December 2016
Touchlight shortlisted for London Award for Innovation
We are delighted to announce that Touchlight has been shortlisted for the London Award for Innovation in the 25th Anniversary London First Awards. See full article here. London First are a non-profit organisation with the mission to make London the best city in the world to do business. They aim to influence national and local government … Continued
6 October 2016
Touchlight awarded Best Emerging UK Synthetic Biotech
We are delighted to announce that Touchlight has been awarded Best Emerging UK Synthetic Biotech Company at the industry-leading OBN awards, reflecting the significant progress we have made in developing our innovative DNA amplification platform. Synbicite press release here.
4 August 2016
Touchlight shortlisted for Best Emerging UK Synthetic Biology Company.
We are delighted to announce that Touchlight has been shortlisted for the OBN 2016 Best Emerging UK Synthetic Biology Company. The OBN Awards celebrate innovation and achievement across the UK life sciences industry and recognising achievements from emerging to late stage R&D companies as well as life sciences investors. A judging panel comprising a range … Continued
17 June 2016
Innovate UK funds Touchlight collaboration with Cobra to optimise AAV manufacture
Cobra Biologics Ltd (Cobra), international CDMO of biologics and pharmaceuticals, and Touchlight, a London based emerging biotech with a novel enzyme technology for large scale production of DNA, are collaborating on a project to optimise the manufacture of Adeno-Associated Virus (AAV) vectors used in the delivery of gene therapy treatments. The collaboration aims to evaluate … Continued
29 April 2016
High-quality laboratories established at Touchlight
Touchlight has developed high-quality dbDNA™ production labs at Hampton capable of providing dbDNA™ to future licensees for feasibility studies.
11 February 2016
University College of London collaboration: DBDNA™ for gene therapy
Touchlight has entered into collaboration with Professor Simon Waddington’s group at the Institute for Women’s Health at UCL. The collaboration aims to investigate the potential to generate conventional gene therapy viral vectors (specifically lentivirus and adeno-associated virus) using doggybones™ in a triple transfection system